Capricor Shares Soar 70% After FDA Signals Openness to Review Duchenne Drug Data

Capricor Shares Soar 70% After FDA Signals Openness to Review Duchenne Drug Data​

Capricor Therapeutics shares surged dramatically after the company announced that the U.S. health regulator is willing to review new data concerning its experimental drug for Duchenne muscular dystrophy. This regulatory pivot has delivered a massive boost to investor sentiment, reversing months of volatility surrounding the life-saving treatment, deramiocel.

The stock, which had previously crashed after an FDA advisory panel voted against the effectiveness data last month, saw significant gains on Friday following the positive update from the drug developer. Capricor's Chief Executive Linda Marban confirmed that the company intends to submit an amendment containing new 24-month data focused on improving upper limb muscle function.

Regulatory U-Turn for Deramiocel​

The previous setback occurred when a panel questioned whether enrolled patients truly had Duchenne-related cardiomyopathy, given their normal heart function at baseline. The FDA advisory board and agency staff had raised concerns about how Capricor measured the trial's main outcomes.

However, some members of the panel had shown more receptivity towards the drug’s arm and hand function data compared to its contested benefits related to cardiac health. The FDA has now signaled its readiness to review this new information before issuing a final decision.

Path Forward and Timeline Extensions​

Marban stated that Capricor is actively working with the FDA on establishing a potential path forward for deramiocel. The agency had previously planned to issue its decision by August 22, but Roth Capital analysts suggest the resubmission will be treated as a major amendment, potentially extending the review timeline by around three months.

The company indicated that it would submit an amendment based on the new muscle function data and is committed to closely collaborating with the FDA throughout this process. This willingness from the agency appears to support the potential for approval, according to analysts at Oppenheimer.

Market Reaction and Analyst Perspectives​

Capricor shares were trading at $7.16 in the morning, a strong rebound after previously being valued at $19.70 prior to last month's negative FDA advisory. The market view is highly positive regarding this regulatory clarity provided by the agency.

Cantor analyst Kristen Kluska labeled the FDA's willingness to review the muscle data a potentially positive surprise. She noted that the agency would have little reason to extend the deadline if it had already decided against approval based on the initial findings.

Financial Stability Amid Regulatory Wait​

Capricor Therapeutics reported possessing $237.9 million in cash as of June. The company confirmed it is currently pacing its commercial launch spending while awaiting definitive regulatory clarity. This financial stability provides a robust foundation as the company navigates this extended review phase with the FDA.